Gilead Acquires German Cancer Biotech Tubulis for Over $3 Billion

Gilead Sciences is acquiring Munich-based biotech Tubulis for more than $3 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, announced Tuesday, April 7, 2026. The deal brings Tubulis' antibody-drug conjugate technology into Gilead's oncology pipeline, highlighting both the therapeutic and commercial promise of these next-generation chemotherapy treatments. This marks Gilead's third major acquisition in early 2026, following a $7.8 billion deal for Arcellx and a $2.18 billion purchase of Ouro Therapeutics announced in March 2026. The aggressive acquisition strategy expands Gilead's portfolio across oncology and autoimmune disease.

Gilead's $3 Billion Acquisition of Tubulis

• ▪The Gilead Sciences acquisition of Tubulis includes an upfront payment of $3.15 billion.
• ▪Gilead Sciences and Tubulis announced the acquisition deal on Tuesday, April 7, 2026.
• ▪The Gilead Sciences acquisition of Tubulis includes up to $1.85 billion in milestone payments.
• ▪Gilead Sciences is acquiring Tubulis for more than $3 billion.
• ▪The Gilead Sciences acquisition of Tubulis will grow Gilead's oncology pipeline.

Antibody-Drug Conjugates as Next-Generation Cancer Treatment

• ▪The Gilead Sciences acquisition of Tubulis highlights the therapeutic promise of antibody-drug conjugates.
• ▪Antibody-drug conjugates are next-generation chemotherapy treatments.
• ▪Tubulis specializes in next-generation chemotherapies.

Gilead's Broader Acquisition Strategy in Biopharma

• ▪Ouro Therapeutics is focused on drugs for autoimmune disease.
• ▪Gilead Sciences is acquiring Ouro Therapeutics for up to $2.18 billion.
• ▪The Gilead Sciences and Arcellx multiple myeloma CAR-T therapy could be approved later in 2026.
• ▪Gilead Sciences and Arcellx had been working together on a multiple myeloma CAR-T therapy.
• ▪Gilead Sciences announced the Arcellx acquisition just months before the Tubulis acquisition announcement in April 2026.
• ▪Gilead Sciences announced in March 2026 that it was buying Ouro Therapeutics.
• ▪Gilead Sciences announced it would acquire Arcellx in a deal worth $7.8 billion.

Perspective of Gilead Sciences

• ▪The Tubulis acquisition strengthens Gilead Sciences' position in the antibody-drug conjugate market.
• ▪Gilead Sciences is pursuing an aggressive acquisition strategy in 2026 to expand its therapeutic portfolio.

Perspective of Biotech industry analysts

• ▪Gilead Sciences' three major acquisitions in early 2026 represent over $13 billion in deal value.
• ▪The $3.15 billion upfront payment for Tubulis demonstrates high valuations for early-stage antibody-drug conjugate companies.
• ▪The Tubulis acquisition reflects growing pharmaceutical industry interest in antibody-drug conjugate platforms.

1 source